January 7, 2021

By Emily Wisner

The Aria team took a break (mostly) from the world of health IT PR for a full two weeks this holiday season. After a year of hard work, a crazy pandemic, and a transition to WFH, we took some well-deserved time to relax. Read about the team’s much needed R&R over the holidays:

Read More

December 18, 2020

Looking ahead to 2021, I am expecting an improvement from 2020.  I know that is not saying much, but there are a lot of crazy dynamics at play in the healthcare industry and the economy as a whole, so it’s very hard to say what to expect, except a lot of change.  That said, here’s what I am watching for in the year to come:

Read More

December 11, 2020

Healthcare is a fascinating field for public relations pros like us, but 2020 proved especially riveting as the COVID-19 health crisis wreaked havoc across the globe. Our clients’ important conferences – and live PR opportunities – were canceled to avoid virus spread, and every day brought another news cycle saturated with challenges for the healthcare industry. Though we had to do some outside of the box thinking and ramp up on all things pandemic overnight, the Aria team secured press opportunities for our clients’ to shine through even the most pervasive doom scrolling.

Read More

December 3, 2020

One of the great things about Aria Marketing is that we get to work with so many technology companies doing amazing things for patients, providers, and the healthcare system in general. One such client is eVideon, a Michigan-based company providing hospitals with interactive patient engagement and digital workflow solutions.

Read More

November 20, 2020

The change of administration resulting from the November election will surely have big implications for the healthcare industry.  Just how big remains to be seen, as Georgia’s two Senate seats and the fate of the Senate majority remain in question.  With or without the Senate, the Biden administration will have a very different agenda than the previous administration with regard to the future of the ACA, pharmaceutical pricing, and many other issues at hand for the US healthcare system.

Read More